You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍下跌 科濟藥業及中生製藥跌逾4%至5% 惟神威藥業逆勢漲半成
恆指及國指終止四連升,今天(3日)反覆回吐,恆指高低見20,475/20,226,現報20,371,回吐28點或0.1%,總成交額955億元。國指高低見6,998/6,885,現報6,931,回吐0.5%,總成交額955億元。 上月尾公布去年多賺三成兼派發今年度第一次中期股息31分人民幣的神威藥業(02877.HK)連升兩天,今天逆行業高見7.85元(暫受制今年1月中旬所創52周高位8.12元),現報7.72元,續漲4.9%。三葉草生物-B(02197.HK)由上市低位止跌回升近1.9%,報1.65元。 其餘醫藥股普遍下跌,尤其是去年少賺近83%但末期股息年增五成至6港仙的藍籌中生製藥(01177.HK)失守250天線(4.33元),最多挫近一成低見3.97元獲承接,現報4.17元,僅回吐5.2%;同為藍籌的藥明生物(02269.HK)續跌3.6%,曾低見46.1元;藍籌翰森製藥(03692.HK)吐近2%,曾低見13.2元。科濟藥業-B(02171.HK)跌4.1%,曾低見11.82元。 康希諾(06185.HK)、金斯瑞(01548.HK)、藥明康德(02359.HK)、威高股份(01066.HK)及康方生物(09926.HK)跌逾1.5%至3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account